Your browser is no longer supported. Please, upgrade your browser.
Exicure, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own0.20% Shs Outstand87.33M Perf Week-13.47%
Market Cap150.12M Forward P/E- EPS next Y-0.61 Insider Trans0.00% Shs Float66.88M Perf Month-31.84%
Income-24.70M PEG- EPS next Q-0.12 Inst Own42.10% Short Float2.75% Perf Quarter-26.75%
Sales16.60M P/S9.04 EPS this Y38.00% Inst Trans-7.86% Short Ratio3.10 Perf Half Y-15.66%
Book/sh0.70 P/B2.39 EPS next Y-24.50% ROA-23.90% Target Price- Perf Year-15.66%
Cash/sh0.91 P/C1.83 EPS next 5Y- ROE-32.70% 52W Range1.38 - 3.30 Perf YTD-5.65%
Dividend- P/FCF- EPS past 5Y3.30% ROI-32.60% 52W High-49.39% Beta-
Dividend %- Quick Ratio6.30 Sales past 5Y47.40% Gross Margin- 52W Low21.01% ATR0.15
Employees54 Current Ratio6.30 Sales Q/Q-66.70% Oper. Margin- RSI (14)29.65 Volatility6.62% 6.76%
OptionableNo Debt/Eq0.27 EPS Q/Q-12.20% Profit Margin- Rel Volume0.58 Prev Close1.70
ShortableYes LT Debt/Eq0.27 Earnings- Payout- Avg Volume593.38K Price1.67
Recom1.50 SMA20-19.79% SMA50-26.17% SMA200-18.06% Volume343,956 Change-1.76%
Dec-18-20Initiated BMO Capital Markets Outperform $6
Nov-20-19Initiated Guggenheim Buy $9
Mar-11-21 10:03AM  
Mar-09-21 08:45AM  
Mar-03-21 07:00AM  
Mar-02-21 12:30PM  
Feb-23-21 07:00AM  
Feb-15-21 08:52AM  
Feb-09-21 07:00AM  
Feb-02-21 07:00AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Jan-04-21 07:00AM  
Dec-29-20 07:00AM  
Dec-28-20 09:15AM  
Dec-23-20 04:44AM  
Dec-21-20 09:15AM  
Dec-11-20 06:00PM  
Nov-16-20 07:00AM  
Nov-12-20 08:50AM  
Nov-09-20 08:10AM  
Nov-06-20 01:03PM  
Oct-19-20 07:00AM  
Oct-05-20 07:00AM  
Oct-01-20 07:00AM  
Sep-22-20 03:31PM  
Sep-16-20 07:00AM  
Sep-10-20 07:00AM  
Aug-25-20 07:00AM  
Aug-12-20 07:00AM  
Aug-05-20 07:00AM  
Jul-05-20 03:30PM  
Jun-29-20 07:00AM  
Jun-22-20 07:00AM  
Jun-18-20 07:00AM  
Jun-16-20 07:00AM  
Jun-04-20 09:46AM  
May-20-20 07:00AM  
May-19-20 07:00AM  
May-15-20 11:50AM  
May-14-20 07:00AM  
May-05-20 07:00AM  
Apr-07-20 07:00AM  
Mar-30-20 04:59PM  
Mar-19-20 10:39AM  
Mar-03-20 07:00AM  
Mar-02-20 07:00AM  
Feb-13-20 02:19PM  
Jan-22-20 12:17PM  
Dec-23-19 04:05PM  
Dec-19-19 09:20AM  
Dec-18-19 04:01PM  
Dec-16-19 07:00AM  
Dec-11-19 08:12AM  
Dec-09-19 04:37PM  
Nov-14-19 08:28AM  
Nov-13-19 09:00AM  
Nov-07-19 07:00AM  
Oct-21-19 04:32PM  
Oct-16-19 07:00AM  
Oct-14-19 07:00AM  
Oct-10-19 03:02PM  
Sep-17-19 04:30PM  
Aug-08-19 07:00AM  
Aug-07-19 07:00AM  
Aug-02-19 10:21AM  
Jun-26-19 06:12PM  
Jun-03-19 07:00AM  
May-22-19 07:00AM  
May-09-19 04:30PM  
May-08-19 04:30PM  
May-03-19 07:00AM  
Apr-30-19 07:00AM  
Mar-26-19 07:00AM  
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAAbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Venkatesan JayDirectorJul 06Option Exercise0.8722,24019,369324,473Jul 08 04:46 PM
AURASENSE LLC10% OwnerJun 12Sale2.8310,19528,85211,257,629Jun 16 09:43 PM
Mirkin Chad A.DirectorJun 12Sale2.8310,19528,85211,257,629Jun 16 09:35 PM
Mirkin Chad A.DirectorMay 20Option Exercise0.6549,64932,27264,649May 21 04:46 PM